At least 27 biotechs and pharmas are slated to report earnings this week. Biotech bellwether Amgen Inc. (NASDAQ:AMGN) is expected to post 2Q14 EPS growth of 10% on a 5% increase in revenues to $4.9 billion, while fellow large-cap biotechs BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) are each anticipated to report a wider loss per share. Vertex's revenues are expected to decline by 58% to $131.9 million due to flagging sales of HCV drug Incivek telaprevir, and BioMarin has guided to higher SG&A in 2014 over 2013 to accommodate the launch of Vimizim elosulfase alfa. Vimizim was approved in the U.S. in February and the EU in April to treat